Skip to main content
Caplight Logo









Elevara Medicines

Elevara Medicines

Private
AltrinchamHealthcare & Life Scienceshttps://www.elevara.com/

Last Round

Series A

Oct 22, 2025

Total Funding Raised

$140M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Elevara Medicines is a clinical-stage biotechnology company developing novel therapeutics to treat rheumatoid arthritis and other chronic inflammatory conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyrheumatoid arthritisCDK4/6 inhibitorclinical-stage biotechfibroblast-like synoviocytesdrug developmentchronic inflammatory diseaseclinical trialssmall-molecule therapybiotech startuporal therapeuticdrug discoveryadd-on therapypharma pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Elevara Medicines Comparables

Compare Elevara Medicines with similar companies based on industry and business-model similarity.

Elevara Medicines comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Astellas Pharma Inc.
74%
Revolo Biotherapeutics
70%
LAPIX Therapeutics
69%

Elevara Medicines Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 22, 2025
Series ASep 1, 2025
SeedMar 1, 2025

Key People

Founding team and executive leadership

Tim Funnell

Founding Team Chief Operating Officer

Founding Team

Elevara Medicines Investors

Notable investors and investment history

Elevara Medicines investors
InvestorRounds
ForbionSeries A
Monograph CapitalSeries A, Seed
Sofinnova PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors increased 51% MoM.

  • Apr 3, 2026

    Monthly visitors grew 64% MoM, from 586 to 959.

Elevara Medicines Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Elevara Medicines Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Elevara Medicines's valuation, stock price, and market status.

Firmographic Details

HeadquartersAltrincham
Employee Range14
Year Founded2025
Last FundingOct 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?